Rewriting the rules for care of MDS and AML patients in the time of COVID-19 |
Apr 2020 |
Leukemia Research Reports |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Revisiting Timing and Decision Modeling for Allogeneic Hematopoietic Stem-Cell Transplantation in Myelodysplastic Syndromes |
Jun 2024 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. |
Jan 2019 |
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
Rethinking clinical trial endpoints in myelodysplastic syndromes. |
Jan 2019 |
Leukemia |
Myelodysplastic Syndromes (MDS) |
Reprogramming identifies functionally distinct stages of clonal evolution in myelodysplastic syndromes |
Apr 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
Recent advances in the diagnosis and treatment of pediatric acquired aplastic anemia |
Mar 2023 |
International Journal of Hematology |
Aplastic Anemia |
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes |
May 2023 |
Journal of Clinical Oncology |
Myelodysplastic Syndromes (MDS) |
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria |
May 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes |
Apr 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
Jun 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |